Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BNL-101
- Development stage
- Preclinical
- Lead developer
- Bionaut Labs
- Modality
- Small Molecules
01
Overview
**BNL-101** is Bionaut Labs' preclinical drug-device combination for local treatment of malignant gliomas, including diffuse intrinsic pontine glioma. It combines the anthracycline cytotoxic drug doxorubicin with a remotely controlled, magnetically propelled Bionaut microscale robot intended to deliver the payload directly to difficult-to-reach CNS tumor sites and reduce systemic exposure. The FDA granted orphan drug designation for BNL-101 for malignant gliomas in pediatric and adult patients. ([prnewswire.com](https://www.prnewswire.com/news-releases/fda-grants-bionaut-labs-orphan-drug-designation-to-bnl-101-for-the-treatment-of-malignant-gliomas-in-pediatric-and-adult-patients-301317815.html))
- Other names
- doxorubicinAdriamycinBionaut-delivered doxorubicin
Beyond the preview
Go deeper on BNL-101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BNL-101.